Hutchison China Meditech Ltd (HCM)

 

HCM Share PerformanceMore

52 week high5,310.00 17/11/17
52 week low1,872.50 18/11/16
52 week change 3,377.50 (179.18%)
4 week volume467,518 25/10/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Notification of Major Holdings

RNS Number: 2412V Hutchison China Meditech Limited 01 November 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached i...

NOTIFICATION OF MAJOR HOLDINGS

RNS Number: 2399V Hutchison China Meditech Limited 01 November 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Hutchison China MediTech Limited; Legal Entity Ide...

Chi-Med starts clinical trial of Inhibitor for gastric cancer patients

Hutchison China MediTech has initiated FRUTIGA, a pivotal phase III clinical trial of fruquintinib in combination with p...

FRUTIGA, a Phase III trial of Fruquintinib

RNS Number: 0641V Hutchison China Meditech Limited 31 October 2017 Press Release ChiMed Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line GastricCancer London: Tuesday , October 31 , 2017: Hutchison China MediTech Limited ("ChiMed") (AIM/Nasdaq: HCM) has initiated FRUTIGA , a pivotal Phase III clinical trial of fru quintinib in combin...

Closing of U.S. Public Offering of ADSs

RNS Number: 0083V Hutchison China Meditech Limited 30 October 2017 Chi-Med Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately US$ 301.3 Million on the Nasdaq Global Select Market London: Monday, October 30, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announced to...

Chi-Med Announces Over-allotment Option

RNS Number: 8546U Hutchison China Meditech Limited 27 October 2017 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Chi-Med Announces the Full Exerc...

Chi-Med prices US public offering

Hutchison China MediTech has announced the pricing of the US public offering of American Depositary Shares on Nasda...

Chi-Med Announces Pricing Raising US$262 million

RNS Number: 6784U Hutchison China Meditech Limited 26 October 2017 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Chi-Med Announces Pricing of U.S...

Latest discussion posts More

  • Re: Revised valuation?

    #250 per share ior close to it s perfectly achievable in my opinion Fast forward 9 years to 2026 Revs (based on a number of Analysts forecasts) = $1046m EBITDA ...
    19-Nov-2017
    David Global
  • Deal

    It is my opinion that the recent fundraise in excess of $300m is much larger than is needed for the current pipeline development , especially given the Commercial platform cash ...
    19-Nov-2017
    David Global
  • Re: Directors dealing info

    current major holders http://www.chi-med.com/investors/shareholders-analysis/ loads of other info on Directors deals in the website and in the reports
    19-Nov-2017
    David Global

Users' HoldingsMore

Users who hold Hutchison China Meditech Ltd also hold..
GLAXOSMITHKLINE20%
RDS 'B'20%
BURFORD CAP LD19%
NATIONAL GRID18%
LLOYDS GRP.17%

Codes & Symbols

ISINKYG4672N1016
SymbolsHCM, LSE:HCM, HCM.L, HCM:LN, LON:HCM, XLON:HCM

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account